Home » Stocks » MOTS

Motus GI Holdings, Inc. (MOTS)

Stock Price: $1.06 USD 0.01 (0.95%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 49.55M
Revenue (ttm) 98,000
Net Income (ttm) -19.26M
Shares Out 32.12M
EPS (ttm) -0.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $1.06
Previous Close $1.05
Change ($) 0.01
Change (%) 0.95%
Day's Open 1.05
Day's Range 1.04 - 1.08
Day's Volume 1,225,970
52-Week Range 0.68 - 2.74

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

- - - - The article states Pure-Vu System is estimated to provide lifetime saving of $833- $992 per patient when compared to standard of care for outpatient colorectal cancer (CRC) screening and surveil...

2 days ago - GlobeNewsWire

Motus GI Holdings, Inc. (MOTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 days ago - Zacks Investment Research

Motus GI Holdings (MOTS) stock is on the rise Friday following clearance from the FDA for one of the company's medical devices. The post MOTS Stock: The Big FDA News That Has Motus GI Holdings Soaring T...

1 week ago - InvestorPlace

Tech penny stocks are back in focus; check these 3 out The post Penny Stocks to Buy? Check These Tech Stocks Out appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other stocks mentioned: CCO, NOK
1 week ago - PennyStocks

FORT LAUDERDALE, Fla., April 30, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve c...

1 week ago - GlobeNewsWire

FORT LAUDERDALE, Fla., April 29, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve c...

1 week ago - GlobeNewsWire

Motus GI Holdings Inc (NASDAQ: MOTS) has submitted a 510(k) application to the FDA for a version of the Pure-Vu System. The new version of the system is compatible with gastroscopes used during upper ga...

1 month ago - Benzinga

Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of 0.00% and -61.29%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

FORT LAUDERDALE, Fla., March 16, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve c...

1 month ago - GlobeNewsWire

FORT LAUDERDALE, Fla., March 15, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve c...

1 month ago - GlobeNewsWire

Motus GI Holdings, Inc. (MOTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

FORT LAUDERDALE, Fla., March 02, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve c...

2 months ago - GlobeNewsWire

FORT LAUDERDALE, Fla., March 01, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve c...

2 months ago - GlobeNewsWire

FORT LAUDERDALE, Fla., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve cl...

3 months ago - GlobeNewsWire

Regulatory approval for enhanced system is a key milestone that supports evaluation of strategic partnership opportunities in the EU - - - U.S. commercial rollout of Pure-Vu® GEN2 System enhancements in...

3 months ago - GlobeNewsWire

Receives additional EU Patent for the Pure-Vu® System that protects the design of its fecal waste evacuation channels Receives additional EU Patent for the Pure-Vu® System that protects the design of it...

3 months ago - GlobeNewsWire

FORT LAUDERDALE, Fla., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve cl...

5 months ago - GlobeNewsWire

Motus GI Holdings, Inc.'s (MOTS) CEO Tim Moran on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

FORT LAUDERDALE, Fla., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve cl...

5 months ago - GlobeNewsWire

FORT LAUDERDALE, Fla., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions to help improv...

6 months ago - GlobeNewsWire

FORT LAUDERDALE, Fla., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve cl...

6 months ago - GlobeNewsWire

FORT LAUDERDALE, Fla., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve cl...

6 months ago - GlobeNewsWire

FORT LAUDERDALE, Fla., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve...

7 months ago - GlobeNewsWire

FORT LAUDERDALE, Fla., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that impro...

7 months ago - GlobeNewsWire

FORT LAUDERDALE, Fla., Aug. 28, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve ...

8 months ago - GlobeNewsWire

Motus GI Holdings, Inc.'s (MOTS) CEO Tim Moran on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of 28.57% and -95.00%, respectively, for the quarter ended June 2020.

8 months ago - Zacks Investment Research

Shares of Motus GI Hldgs (NASDAQ: MOTS) were flat after the company reported Q2 results.

8 months ago - Benzinga

FORT LAUDERDALE, Fla., July 21, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improv...

9 months ago - GlobeNewsWire

FORT LAUDERDALE, Fla., June 15, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve ...

10 months ago - GlobeNewsWire

Live moderated video webcast discussion with CEO, Tim Moran on Monday, June 15, at 2:00 PM ET, immediately followed by an interactive Q&A session Live moderated video webcast discussion with CEO, Tim Mo...

10 months ago - GlobeNewsWire

Motus GI Holdings, Inc. (MOTS) CEO Tim Moran on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of -4.55% and -81.33%, respectively, for the quarter ended March 2020.

11 months ago - Zacks Investment Research

FORT LAUDERDALE, Fla., May 14, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve...

11 months ago - GlobeNewsWire

FORT LAUDERDALE, Fla., May 05, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve c...

1 year ago - GlobeNewsWire

Motus GI Holdings, Inc. (MOTS) CEO Tim Moran on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

FORT LAUDERDALE, Fla., March 30, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that impro...

1 year ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Motus GI Holdings.

1 year ago - Zacks Investment Research

Motus GI Holdings, Inc. (MOTS) CEO Tim Moran on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of 28.00% and -97.00%, respectively, for the quarter ended September 2019.

1 year ago - Zacks Investment Research

The GuruFocus All-in-One Screener can be used to find insider trades from the past week.

Other stocks mentioned: CHRS, DDMXU, FND, HDS, KRTX, OCX
1 year ago - GuruFocus

About MOTS

Motus GI Holdings, Inc., a medical technology company, provides endoscopy solutions that enhance clinical outcomes and the cost-efficiency associated with colonoscopy in the United States and Israel. Its flagship product is the Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The company was incorporated in 2016 and is based in Fort Lauderdale, Florida.

Industry
Diagnostics & Research
IPO Date
Feb 14, 2018
CEO
Timothy Moran
Employees
24
Stock Exchange
NASDAQ
Ticker Symbol
MOTS
Full Company Profile

Financial Performance

In 2020, MOTS's revenue was $98,000, a decrease of -8.41% compared to the previous year's $107,000. Losses were -$19.26 million, -16.59% less than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for MOTS stock is "Buy." The 12-month stock price forecast is 2.42, which is an increase of 128.30% from the latest price.

Price Target
$2.42
(128.30% upside)
Analyst Consensus: Buy